Medline ® Abstract for Reference 17
of 'Clinical manifestations and diagnosis of heart failure with preserved ejection fraction'
Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline.
Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM
J Am Coll Cardiol. 2003;41(9):1510.
OBJECTIVES: We evaluated the six-month clinical trajectory of patients hospitalized for heart failure (HF) with preserved ejection fraction (EF), as the natural history of this condition has not been well established. We compared mortality, hospital readmission, and changes in functional status in patients with preserved versus depressed EF.
BACKGROUND: Although the poor prognosis of HF with depressed EF has been extensively documented, there are only limited and conflicting data concerning clinical outcomes for patients with preserved EF.
METHODS: We prospectively evaluated 413 patients hospitalized for HF to determine whether EF>or=40% was an independent predictor of mortality, readmission, and the combined outcome of functional decline or death.
RESULTS: After six months, 13% of patients with preserved EF died, compared with 21% of patients with depressed EF (p = 0.02). However, the rates of functional decline were similar among those with preserved and depressed EF (30% vs. 23%, respectively; p = 0.14). After adjusting for demographic and clinical covariates, preserved EF was associated with a lower risk of death (hazard ratio [HR]0.49, 95% confidence interval [CI]0.26 to 0.90; p = 0.02), but there was no difference in the risk of readmission (HR 1.01, 95% CI 0.72 to 1.43; p = 0.96) or the odds of functional decline or death (OR 1.01, 95% CI 0.59 to 1.72; p = 0.97).
CONCLUSIONS: Heart failure with preserved EF confers a considerable burden on patients, with the risk of readmission, disability, and symptoms subsequent to hospital discharge, comparable to that of HF patients with depressed EF.
Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Connecticut, USA.